Lantern Pharma Q2 net loss narrows to $4.33M; LP-184 Phase 1a complete, complete responses in two trials

Lantern Pharma Inc.

2025-Q2 EPS reported -$0.82

Q2 2025 net loss $4.33M ($0.40/share) vs $4.96M ($0.46) a year ago; cash $15.9M as of June 30, 2025.
LP-184 Phase 1a enrollment complete (65 patients); MTD and RP2D established; advancing to Phase 1b/2 in TNBC and bladder cancer.
LP-300 HARMONIC trial shows complete response in a 70-year-old NSCLC patient who failed three prior therapies.
LP-284 achieves complete metabolic response in heavily pretreated DLBCL patient after two cycles.
Cash runway extends at least into June 2026; no quarterly earnings call planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.